Sat, Feb 28, 2015, 7:41 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • wilderguide wilderguide Jul 24, 2013 1:27 PM Flag

    Ganetespib/Docetaxel combo improves OS in pre specified pops

    Dr Suresh Ramalingam at targetedhcdotcom 7/24/13 on HSP90i with Ganetespib.

    "An extension phase of GALAXY-1, focusing on biomarker analysis, recently completed accrual, with results expected to be reported later this year. In addition, the phase III GALAXY-2 trial will compare second-line ganetespib plus docetaxel versus docetaxel alone in advanced lung cancer patients with adenocarcinoma histology and will only enroll patients who are more than 6 months past a diagnosis of advanced disease. The target enrollment is 500 patients, and the primary endpoint is overall survival."

    I'm with this guy. I think SNTA has powered this extension cohort to unquestionably tease out a statsig OS signal in adv lung cancer populations with histologic adenocarcinoma.

2.40-0.020(-0.83%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.